百时美施贵宝Bristol Myers Squibb Co. (BMY) 2019年年度报告「NYSE」.pdf

1、2 0 1 9 A N N U A L R E P O R TWere inspired by a single vision:The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses.In addition,there is no guarantee that potential drug

2、s or indications still in development will receive regulatory approval.Our MissionTo discover,develop and deliver innovative medicines that help patients prevail over serious diseasesOur VisionTo be the worlds leading biopharma company that transforms patients lives through scienceBristol Myers Squi

3、bb 2019 Annual ReportMade Strong is a registered mark of the Made Strong organization.Used with permission.Letter from the Chairman and CEOAt Bristol Myers Squibb,we are inspired by our mission to discover,develop and deliver innovative medicines that help patients prevail over serious diseases.Ever

4、y day,we focus on innovations that drive meaningful breakthroughs so we can bring life-saving medicines to people around the world.2019 was a transformativeyear for us.*Full Year GAAP:*Includes Celgene product revenues from November 20,2019,which was the date of the closing of the acquisition,throug

5、h December 31,2019.See“Quarterly Package of Financial Information,”available on Forma Full Year:Reflects product revenues for the period prior to November 20,2019,which was the date of the Celgene acquisition.All product revenues prior to November 20,2019 have been recast to exclude foreign currency

6、 hedge gains and losses.See“Quarterly Package of Financial Information”available on POWER OF FOLLOWING THE SCIENCEWe start this next chapter at a time when unprecedented scientific breakthroughs are advancing the treatment of disease as never before.Bristol Myers Squibb is well positioned in scienti